Semaglutide Reduces Diuretic Need by 17% in Heart Failure Patients While Improving Symptoms Across All Diuretic Groups
In 1,145 obese HFpEF patients, semaglutide consistently improved symptoms and weight regardless of baseline diuretic use, with especially pronounced benefits in patients on loop diuretics and a 17% reduction in loop diuretic dose vs a 2.4% increase on placebo.
Quick Facts
What This Study Found
Weight loss consistent across diuretic groups (-6.9% to -8.8%, interaction P=0.39). KCCQ improvement greater in loop diuretic users (+9.3 vs +4.7 points, P=0.042). Loop diuretic dose decreased 17% with semaglutide vs +2.4% with placebo (P<0.0001). Semaglutide: OR 2.67 for dose reduction, OR 0.35 for dose increase. All secondary endpoints consistent across diuretic subgroups.
Key Numbers
1,145 patients pooled from STEP-HFpEF and STEP-HFpEF-DM. Published in European Heart Journal.
How They Did This
Prespecified pooled analysis of STEP-HFpEF and STEP-HFpEF-DM (n=1,145). Participants stratified by baseline diuretic use: no diuretic (n=220), non-loop only (n=223), loop ≤40 mg furosemide equivalents (n=174), loop >40 mg (n=528). Assessed efficacy endpoints and loop diuretic dose changes over 52 weeks.
Why This Research Matters
Diuretic reduction in heart failure is a meaningful clinical outcome — it suggests improved fluid balance and cardiac function, not just symptom masking. That semaglutide allows patients to reduce their diuretic doses while improving symptoms indicates genuine disease modification.
The Bigger Picture
This analysis suggests semaglutide doesn't just improve HFpEF symptoms — it may alter the underlying disease trajectory, allowing patients to reduce the diuretic doses they depend on. For heart failure management, reducing medication burden while improving outcomes represents a true therapeutic advance.
What This Study Doesn't Tell Us
Subgroup analysis — though prespecified, subgroup sizes vary. The diuretic dose reduction doesn't necessarily mean improved heart failure per se (could reflect weight-related fluid loss). Open-label nature of diuretic adjustments may introduce bias. 52-week follow-up may not capture long-term diuretic trajectory.
Questions This Raises
- ?Could semaglutide eventually allow some HFpEF patients to discontinue diuretics entirely?
- ?Is the greater symptom benefit in loop diuretic users because these patients had more room for improvement?
- ?Does the diuretic dose reduction translate to fewer diuretic-related adverse effects (electrolyte abnormalities, kidney function)?
Trust & Context
- Key Stat:
- 17% diuretic dose reduction Semaglutide reduced loop diuretic doses by 17% while placebo patients needed 2.4% more, suggesting genuine improvement in fluid balance and cardiac function
- Evidence Grade:
- Rated strong: prespecified pooled analysis of two rigorous RCTs, published in European Heart Journal. Subgroup findings are consistent across endpoints.
- Study Age:
- Published in 2024 in European Heart Journal. Extends STEP-HFpEF evidence by demonstrating semaglutide benefits across the full spectrum of diuretic use.
- Original Title:
- Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
- Published In:
- European heart journal, 45(35), 3254-3269 (2024)
- Authors:
- Shah, Sanjiv J(11), Sharma, Kavita(3), Borlaug, Barry A(17), Butler, Javed, Davies, Melanie, Kitzman, Dalane W, Petrie, Mark C, Verma, Subodh, Patel, Shachi, Chinnakondepalli, Khaja M, Einfeldt, Mette N, Jensen, Thomas J, Rasmussen, Søren, Asleh, Rabea, Ben-Gal, Tuvia, Kosiborod, Mikhail N
- Database ID:
- RPEP-09241
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide reduce the need for heart failure medications?
Yes — in this study of 1,145 patients, semaglutide reduced loop diuretic doses by 17% while improving heart failure symptoms. Patients on semaglutide were nearly 3 times more likely to have their diuretic dose reduced compared to placebo.
Does semaglutide work for heart failure patients already on diuretics?
Absolutely — semaglutide improved symptoms, weight, and exercise capacity regardless of baseline diuretic use. Patients already on loop diuretics actually showed the greatest symptom improvements.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09241APA
Shah, Sanjiv J; Sharma, Kavita; Borlaug, Barry A; Butler, Javed; Davies, Melanie; Kitzman, Dalane W; Petrie, Mark C; Verma, Subodh; Patel, Shachi; Chinnakondepalli, Khaja M; Einfeldt, Mette N; Jensen, Thomas J; Rasmussen, Søren; Asleh, Rabea; Ben-Gal, Tuvia; Kosiborod, Mikhail N. (2024). Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.. European heart journal, 45(35), 3254-3269. https://doi.org/10.1093/eurheartj/ehae322
MLA
Shah, Sanjiv J, et al. "Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.." European heart journal, 2024. https://doi.org/10.1093/eurheartj/ehae322
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide and diuretic use in obesity-related heart failur..." RPEP-09241. Retrieved from https://rethinkpeptides.com/research/shah-2024-semaglutide-and-diuretic-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.